Roivant Sciences (ROIV) Equity Average (2020 - 2026)

Roivant Sciences has reported Equity Average for 7 years, with the latest figure at $5.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Equity Average changed 0.42% year-over-year to $5.1 billion; the trailing twelve-month figure through Mar 2026 stood at $5.1 billion (changed 0.42% YoY), and the FY2026 full-year result was $5.1 billion, changed 0.42% from the prior year.
• Equity Average for Q1 2026 stood at $5.1 billion, up from $4.9 billion in the prior quarter.
• The five-year high for Equity Average was $6.5 billion in Q1 2024, with the low at $1.3 billion in Q3 2023.
• Historically, Equity Average has averaged $3.8 billion across 5 years, with a median of $4.8 billion in 2025.
• Annual changes were most pronounced in 2022 — Equity Average sank 37.09% — and 2024, when it jumped 331.44%.
• Roivant Sciences' Equity Average stood at $1.5 billion in 2022, then jumped by 168.94% to $4.0 billion in 2023, then soared by 40.53% to $5.6 billion in 2024, then dropped by 12.02% to $4.9 billion in 2025, then increased by 4.98% to $5.1 billion in 2026.
• The last three Equity Average figures came in at $5.1 billion (Q1 2026), $4.9 billion (Q4 2025), and $4.8 billion (Q3 2025), per Business Quant data.